Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn’s disease patients

Chen, Yueying; Feng, Jing; Tian, Yue; Qiao, Yu; Shen, Jun

doi:10.1016/j.biopha.2021.112076

Cited by 5 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical goals for CD include improvements in laboratory indicators, relief of clinical symptoms, and mucosal healing. Patients in clinical remission may experience a secondary loss of response to biologics and the recurrence of clinical symptoms [18][19][20][21][22]. Mucosal healing can signi cantly improve disease prognosis [23,24]; therefore, mucosal healing should be considered as a therapeutic target in children with CD.…”

Section: Discussionmentioning

confidence: 99%

A Novel Nomogram for Predicting Mucosal Healing in Crohn's Disease in Children

Wang,

Han,

Guo

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: To analyze the clinical risk factors and establish a non-invasive nomogram clinical prediction model for mucosal healing in children with Crohn's disease. Methods:The clinical data of patients aged 1–14 years with Crohn's disease were retrospectivelyanalyzed. Patients were divided into the mucosal healing and non-mucosal healing groups. General data, clinical symptoms, and laboratory examination results of the two groups were compared. The risk factors affecting mucosal healing were analyzed statistically, and nomogram models were established. Results: From January 2011 to June 2023, a total of 74 patients who were continuously diagnosed with Crohn's disease and underwent endoscopy and follow-up after treatment were included in the study. There were 41 patients in the mucosal healing group and 33 in the non-mucosal healing group. Multivariate logistic regression analysis revealed that the erythrocyte sedimentation rate (ESR), platelet-to-lymphocyte ratio (PLR),and C-reactive protein-to-albumin ratio (CAR) were independent risk factors for mucosal healing; thus, they were included in the prediction model. A nomogram was constructed based on the results of the multivariate analysis. The area under the receiver operating characteristic curve of this model was 0.942 (95% confidence interval: 0.842–0.950). The Hosmer–Lemeshow test showed that the decision graph had good calibration (P=0.708). Conclusion:A nomogram model was established based on three related factors (ESR, PLR, and CAR), which can be used to predict mucosal healing in children with Crohn’s disease after treatment, thus reducing the frequency of endoscopic examination.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Nomogram for Predicting Mucosal Healing in Crohn's Disease in Children

Wang,

Han,

Guo

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Finally, a nomogram based on bioelectrical impedance analysis indexes (based on body composition parameters) and laboratory markers (haemoglobin, albumin, serum iron) could predict SLR to infliximab in bio-naïve CD patients at 54 weeks. 238 Other nomograms have been proposed to predict response to treatment but were based on factors other than those present at baseline. 276 Machine learning belongs to the field of artificial intelligence and refers to the ability of computers to learn to make decisions or detect patterns from data, without explicitly being programmed.…”

Section: Therapeutic Advances In Gastroenterologymentioning

confidence: 99%

“… 161 Finally, nomograms based on radiomics were established to predict mucosal healing or SLR with infliximab in CD patients. 236 – 238 Zhu et al 237 indeed attempted to predict mucosal healing in biologic-naïve CD patients treated with infliximab using clinical factors and radiomics features. Their clinical radiomics nomogram combined disease duration and a computed tomography enterography (CTE)-based radiomics signature at baseline and performed well to predict mucosal healing in CD patients after 26 weeks of infliximab treatment.…”

Section: Choosing the Appropriate Treatmentmentioning

confidence: 99%

“… 237 Feng et al 236 also established and validated a nomogram based on an MRI-based radiomic index able to detect change in iron metabolism to identify CD patients at risk of SLR to infliximab. Chen et al 238 also developed a radiomic nomogram with eight radiographic features to predict loss of response to infliximab in CD patients.…”

Section: Choosing the Appropriate Treatmentmentioning

confidence: 99%

Section: Choosing the Appropriate Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Precision medicine and drug optimization in adult inflammatory bowel disease patients

Vieujean

Louis

2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) encompass two main entities including ulcerative colitis and Crohn’s disease. Although having a common global pathophysiological mechanism, IBD patients are characterized by a significant interindividual heterogeneity and may differ by their disease type, disease locations, disease behaviours, disease manifestations, disease course as well as treatment needs. Indeed, although the therapeutic armamentarium for these diseases has expanded rapidly in recent years, a proportion of patients remains with a suboptimal response to medical treatment due to primary non-response, secondary loss of response or intolerance to currently available drugs. Identifying, prior to treatment initiation, which patients are likely to respond to a specific drug would improve the disease management, avoid unnecessary side effects and reduce the healthcare expenses. Precision medicine classifies individuals into subpopulations according to clinical and molecular characteristics with the objective to tailor preventative and therapeutic interventions to the characteristics of each patient. Interventions would thus be performed only on those who will benefit, sparing side effects and expense for those who will not. This review aims to summarize clinical factors, biomarkers (genetic, transcriptomic, proteomic, metabolic, radiomic or from the microbiota) and tools that could predict disease progression to guide towards a step-up or top-down strategy. Predictive factors of response or non-response to treatment will then be reviewed, followed by a discussion about the optimal dose of drug required for patients. The time at which these treatments should be administered (or rather can be stopped in case of a deep remission or in the aftermath of a surgery) will also be addressed. IBD remain biologically complex, with multifactorial etiopathology, clinical heterogeneity as well as temporal and therapeutic variabilities, which makes precision medicine especially challenging in this area. Although applied for many years in oncology, it remains an unmet medical need in IBD.

show abstract

A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn’s disease patients treated with infliximab

Zhu

Wang

et al. 2022

Eur Radiol

View full text Add to dashboard Cite

Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn’s disease patients

Cited by 5 publications

References 47 publications

A Novel Nomogram for Predicting Mucosal Healing in Crohn's Disease in Children

A Novel Nomogram for Predicting Mucosal Healing in Crohn's Disease in Children

Precision medicine and drug optimization in adult inflammatory bowel disease patients

A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn’s disease patients treated with infliximab

Contact Info

Product

Resources

About